Form 4: Indivior CFO Ryan Preblick Reports Significant Equity Grants

Indivior Pharmaceuticals' Chief Financial Officer, Ryan Preblick, reported the acquisition of 37,358 restricted stock units and 113,510 performance stock units.

Summary

• Ryan Preblick, Chief Financial Officer of Indivior Pharmaceuticals, Inc. (INDV), reported the acquisition of 37,358 shares of Common Stock on February 10, 2026, through a grant of restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one share of common stock, vesting in three equal annual installments beginning on February 10, 2027, subject to continued service.
• Preblick also reported the acquisition of 113,510 Performance Stock Units on February 9, 2026, following the certification of performance conditions for an award granted on March 3, 2023.
• These Performance Stock Units will vest on March 3, 2026, subject to continued employment, and will then be subject to an additional two-year Holding Period before the shares are released.
• Following these transactions, Preblick beneficially owns 317,940 shares of Common Stock and 113,510 Performance Stock Units.
• A Power of Attorney was executed on February 9, 2026, appointing Jeffrey Burris, Alice Givens, and David Wisniewski to execute and file SEC Forms 3, 4, and 5 on behalf of Ryan Preblick.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development as it signifies continued executive commitment and aligns the CFO's interests with long-term shareholder value through equity compensation.

Positives

• The equity grants align the Chief Financial Officer's interests with long-term shareholder value, incentivizing sustained performance.
• The vesting schedules and holding periods encourage executive retention and focus on the company's future success.

Risks

• The vesting of both Restricted Stock Units and Performance Stock Units is contingent upon the Reporting Person's continued service and employment with the Issuer.
• Performance Stock Units are subject to a two-year Holding Period after vesting, delaying the executive's ability to realize value from the shares.

Future Outlook

The filing outlines future vesting schedules for equity awards, with Restricted Stock Units vesting in three equal annual installments starting February 10, 2027, and Performance Stock Units vesting on March 3, 2026, followed by a two-year holding period.

Industry Context

StockSavvy.ai notes that equity grants, such as Restricted Stock Units and Performance Stock Units, are a common and widely accepted practice in executive compensation across various industries. These grants are designed to align the interests of key management personnel with those of shareholders, fostering long-term value creation and executive retention.

Comparison to Industry Standards

• Equity compensation, including RSUs and PSUs, is a standard component of executive remuneration packages across the pharmaceutical and broader corporate sectors, comparable to practices at companies like Pfizer, Johnson & Johnson, and Merck, which utilize similar long-term incentive structures.
• The vesting schedules and performance conditions are typical for such awards, aiming to incentivize sustained performance and commitment over several years, consistent with global benchmarks for executive compensation.

Corporate Governance

Related Party Transactions

• The grant of 37,358 Restricted Stock Units and 113,510 Performance Stock Units to Ryan Preblick, the Chief Financial Officer, constitutes a related-party transaction as part of his executive compensation package.

Stakeholder Impact

• Shareholders: Benefit from the alignment of executive incentives with long-term company performance and value creation.
• Employees: The equity grants to a key executive may signal stability and confidence in the company's future direction.

Next Steps

• Continued service of the Reporting Person with the Issuer for vesting of equity awards.
• First annual installment of Restricted Stock Units to vest on February 10, 2027.
• Performance Stock Units to vest on March 3, 2026, followed by a two-year holding period until March 3, 2028.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation grants to a key executive, which is a standard practice for aligning management incentives with shareholder interests. It does not provide new operational or financial information that would alter the fundamental investment thesis for Indivior Pharmaceuticals, Inc., thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Indivior Pharmaceuticals, INDV, Ryan Preblick, CFO, Form 4, SEC filing, restricted stock units, performance stock units, equity compensation, insider transaction